$CAMT

Eisenberg Moshe sold $713K of CAMT

Eisenberg Moshe (Chief Financial Officer) sold 4,404 shares of CAMTEK LTD (CAMT) at an average of $161.90 ($160.06–$172.67, $0.71M total) across 2 trades over 2026-08-11 to 2026-08-12.

Original reporting
SEC EDGAR · Eisenberg Moshe
Published Aug 13, 2026, 2:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 2:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAMT
Neutral
medium confidence
Mentioned
$CAMT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAMTNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details and the absence of a pre-arranged 10b5-1 plan in the filing summary.

02

Market read

Traders may briefly reassess CAMT sentiment due to the insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The filing does not state reasons for the sale, and the post-transaction holdings (16,239 shares) suggest the CFO did not exit the position.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-13, covering sales on 2026-08-11 to 2026-08-12

Background

The article is an SEC Form 4 insider transaction report for CAMTEK (CAMT).

Company-level read

Ticker impact

$CAMTNeutralMedium confidence
Context

CAMTEK CFO Eisenberg Moshe sold $713,024 of CAMT shares in two open-market trades at $160.0561 to $172.6717.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than new fundamentals.

Evidence & confidence

Form 4 provides transaction details (size, dates, prices) but no new operating, guidance, or regulatory information. Insider sales can be informational, yet the article lacks context on motives or material corporate developments.

Market effects

No clear sector read-through from a single insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is not tied to a disclosed 10b5-1 plan, some traders may overinterpret it as bearish, even though insider sales are often non-informational.

Key entities

  • CAMTEK LTD

    Company whose insider transaction is disclosed via Form 4.

  • Eisenberg Moshe

    Chief Financial Officer reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAMTMed

CAMTEK LTD (CAMT): Financial results for FY

CAMTEK LTD (CAMT) furnished an SEC Form 6-K — earnings release. Yes ☐ No ☒ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. This Form 6-K, including all exhibits hereto, is hereby incorporated by r

$ESLTMed

Tue: Rate cut lifts market

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

$CRDOMed

3 Under-the-Radar AI Stocks Wall Street Is Missing

Credo Technology (CRDO) reported Q4 2026 revenue of $437M, up 157% YoY, with guidance for 80% YoY growth in 2027. Astera Labs (ALAB) saw Q2 2026 revenue of $392.4M, up 104% YoY, with Scorpio X series ramping ahead of schedule. Camtek (CAMT) reported Q2 2026 revenue of $133.24M, up 8% YoY, with a strong order book extending into 2027.

$CAMTMedAI 8/10

Camtek (CAMT) Posted Record Q2 Revenue, Is The AI Upside Already Priced In?

Camtek (CAMT) reported record Q2 revenue of $600M+ year-to-date, driven by AI-related advanced packaging demand. The company issued upbeat Q3 guidance, contributing to a 17.55% monthly and 48.74% year-to-date stock price increase. Analysts debate its valuation, with some seeing it as 8.3% undervalued at $171.80, while others suggest it's overvalued based on discounted cash flow models.